Ruben Mesa, MD

Articles

Dr. Mesa on the Impact of Molecular Biology on Therapeutic Development in Myelofibrosis

September 11th 2021

Ruben A. Mesa, MD, discusses the impact of molecular biology on therapeutic development in myelofibrosis.

Dr. Mesa on the Unique Characteristics of Pacritinib in Myelofibrosis

June 24th 2021

Ruben A. Mesa, MD, discusses the unique characteristics of pacritinib in the treatment of patients with myelofibrosis.

Dr. Mesa on Data With Momelotinib in Transfusion Independence Responders in Myelofibrosis

June 11th 2021

Ruben A. Mesa, MD, discusses results seen with momelotinib in patients with transfusion-independent myelofibrosis, as demonstrated in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.

Dr. Mesa on the Anticipated Utility of Momelotinib in Myelofibrosis

December 7th 2020

Ruben A. Mesa, MD, discusses the anticipated utility of momelotinib in myelofibrosis.

Dr. Mesa on the Rationale for the Earlier Use of Ruxolitinib in Myelofibrosis

October 16th 2020

Ruben A. Mesa, MD, discusses the rationale for the earlier use of ruxolitinib in myelofibrosis.

Dr. Mesa on Emerging Therapies in Myelofibrosis

September 23rd 2020

Ruben A. Mesa, MD, discusses emerging therapies in myelofibrosis.

Dr. Mesa on Mitigating Racial Disparities in MPN Clinical Trials

August 5th 2020

Ruben A. Mesa, MD, discusses mitigating racial disparities in myeloproliferative neoplasm clinical trials.

Dr. Mesa on the Utility of Ruxolitinib Versus Fedratinib in Myelofibrosis

April 21st 2020

Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis and baseline thrombocytopenia.

Dr. Mesa on Unanswered Questions Regarding JAK Inhibitors in Myelofibrosis

April 11th 2020

Ruben Mesa, MD, discusses unanswered questions regarding JAK inhibitors in myelofibrosis.

Dr. Mesa on Challenges in Myelofibrosis Treatment

April 8th 2020

Ruben Mesa, MD, discusses remaining challenges in treating myelofibrosis.

Dr. Mesa on Investigative Therapies in Myelofibrosis

March 26th 2020

Ruben Mesa, MD, discusses therapiesunder investigation in myelofibrosis.

Dr. Mesa on the Utility of Fedratinib for Patients With Myelofibrosis Who Progress on Ruxolitinib

March 16th 2020

Ruben Mesa, MD, discusses the utility of fedratinib for patients with myelofibrosis who progress on first-line ruxolitinib.

Dr. Mesa on Challenges With JAK Inhibitors in Myelofibrosis

March 14th 2020

Ruben Mesa, MD, discusses the challenges with using JAK inhibitors in myelofibrosis.

Dr. Mesa on the Safety Profiles of JAK Inhibitors in Myelofibrosis

February 25th 2020

Ruben Mesa, MD, discusses the adverse events of ruxolitinib and fedratinib in myelofibrosis.

Dr. Mesa on the FDA Approval of Fedratinib in Myelofibrosis

January 17th 2020

Ruben Mesa, MD, discusses theapproval of a second JAK inhibitor, fedratinib, to join ruxolitinib as a treatment option for patients with myelofibrosis.

Dr. Mesa on Ruxolitinib Vs Fedratinib in Myelofibrosis Treatment

October 12th 2019

Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in treating patients with myelofibrosis.

Dr. Mesa Discusses the Management of Patients With MPNs

April 14th 2018

Ruben Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the management of patients with myeloproliferative neoplasms.

Dr. Mesa Discusses Emerging Treatments for MPNs

April 5th 2018

Ruben Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses emerging treatment for myeloproliferative neoplasms (MPNs).

Dr. Mesa Discusses the Treatment Landscape for MPNs

March 22nd 2018

Ruben Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the treatment landscape for patients with myeloproliferative neoplasms (MPNs).

Dr. Mesa on Guideline Updates in Polycythemia Vera and Essential Thrombocythemia

October 8th 2017

Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.